MX2017008875A - Anticuerpos biespecificos contra cd3 y cd20. - Google Patents
Anticuerpos biespecificos contra cd3 y cd20.Info
- Publication number
- MX2017008875A MX2017008875A MX2017008875A MX2017008875A MX2017008875A MX 2017008875 A MX2017008875 A MX 2017008875A MX 2017008875 A MX2017008875 A MX 2017008875A MX 2017008875 A MX2017008875 A MX 2017008875A MX 2017008875 A MX2017008875 A MX 2017008875A
- Authority
- MX
- Mexico
- Prior art keywords
- bispecific antibodies
- antibodies against
- express
- diseases
- cells
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Abstract
Se describen anticuerpos biespecíficos dirigidos a CD3 y CD20 y usos de tales anticuerpos biespecíficos, en particular uso de los mismos en el tratamiento de enfermedades en las cuales el direccionado específico y eliminación mediada por célula T de células que expresan CD20 se desean.
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/EP2015/050276 WO2015104346A1 (en) | 2014-01-09 | 2015-01-08 | Humanized or chimeric cd3 antibodies |
DKPA201500412 | 2015-07-15 | ||
DKPA201500413 | 2015-07-15 | ||
DKPA201500415 | 2015-07-16 | ||
DKPA201500416 | 2015-07-16 | ||
PCT/EP2016/050296 WO2016110576A1 (en) | 2015-01-08 | 2016-01-08 | Bispecific antibodies against cd3 and cd20 |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2017008875A true MX2017008875A (es) | 2017-09-27 |
Family
ID=56355550
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2017008875A MX2017008875A (es) | 2015-01-08 | 2016-01-08 | Anticuerpos biespecificos contra cd3 y cd20. |
MX2022004082A MX2022004082A (es) | 2015-01-08 | 2017-07-04 | Anticuerpos biespecificos contra cd3 y cd20. |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2022004082A MX2022004082A (es) | 2015-01-08 | 2017-07-04 | Anticuerpos biespecificos contra cd3 y cd20. |
Country Status (14)
Country | Link |
---|---|
US (2) | US10544220B2 (es) |
EP (1) | EP3242682A1 (es) |
JP (3) | JP6853176B2 (es) |
KR (1) | KR20170128222A (es) |
CN (2) | CN107660214B (es) |
AU (2) | AU2016205967B2 (es) |
BR (1) | BR112017014551A2 (es) |
CA (1) | CA2973159A1 (es) |
EA (1) | EA201791554A1 (es) |
IL (2) | IL253166B (es) |
MX (2) | MX2017008875A (es) |
SG (1) | SG11201705496SA (es) |
UA (1) | UA120286C2 (es) |
WO (1) | WO2016110576A1 (es) |
Families Citing this family (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11180572B2 (en) | 2012-07-06 | 2021-11-23 | Genmab B.V. | Dimeric protein with triple mutations |
US10465006B2 (en) | 2013-07-05 | 2019-11-05 | Genmab A/S | Humanized or chimeric CD3 antibodies |
DK3083689T3 (da) | 2013-12-17 | 2020-08-03 | Genentech Inc | Anti-CD3-antistoffer og fremgangsmåder til anvendelse |
US9751946B2 (en) | 2014-09-12 | 2017-09-05 | Genentech, Inc. | Anti-CLL-1 antibodies and immunoconjugates |
TWI731861B (zh) | 2015-06-16 | 2021-07-01 | 美商建南德克公司 | FcRH5之人源化及親和力成熟抗體及使用方法 |
WO2016204966A1 (en) | 2015-06-16 | 2016-12-22 | Genentech, Inc. | Anti-cd3 antibodies and methods of use |
CN107847568B (zh) | 2015-06-16 | 2022-12-20 | 豪夫迈·罗氏有限公司 | 抗cll-1抗体和使用方法 |
UA128057C2 (uk) | 2015-07-15 | 2024-03-27 | Ґенмаб А/С | Гуманізоване або химерне антитіло, яке зв'язує cd3 людини |
MX2018002226A (es) | 2015-08-28 | 2018-03-23 | Amunix Operating Inc | Ensamble de polipeptido quimerico y metodos para hacer y usar el mismo. |
AR106188A1 (es) | 2015-10-01 | 2017-12-20 | Hoffmann La Roche | Anticuerpos anti-cd19 humano humanizados y métodos de utilización |
EP3252078A1 (en) * | 2016-06-02 | 2017-12-06 | F. Hoffmann-La Roche AG | Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer |
TW201902512A (zh) * | 2016-06-02 | 2019-01-16 | 瑞士商赫孚孟拉羅股份公司 | 治療方法 |
JP7083819B2 (ja) * | 2016-09-30 | 2022-06-13 | セントレ ナショナル デ ラ レセルシュ シャンティフィク | 細胞マーカー |
AU2017361081A1 (en) | 2016-11-15 | 2019-05-23 | Genentech, Inc. | Dosing for treatment with anti-CD20/anti-CD3 bispecific antibodies |
EP3559034B1 (en) * | 2016-12-20 | 2020-12-02 | H. Hoffnabb-La Roche Ag | Combination therapy of anti-cd20/anti-cd3 bispecific antibodies and 4-1bb (cd137) agonists |
CN113896797B (zh) * | 2017-08-01 | 2023-05-09 | Ab工作室有限公司 | 双特异性抗体及其用途 |
MX2020001198A (es) * | 2017-08-04 | 2020-09-07 | Genmab As | Agentes de union que se unen a ligando 1 de muerte programada (pd-l1) y grupo de diferenciacion 137 (cd137) y uso de los mismos. |
EP3668898B1 (en) * | 2017-08-14 | 2023-07-05 | MorphoSys AG | Humanized antibodies for cd3 |
CN107501412A (zh) * | 2017-10-11 | 2017-12-22 | 深圳精准医疗科技有限公司 | 突变型双特异性抗体及其应用 |
AU2019218959A1 (en) | 2018-02-08 | 2020-09-03 | Genentech, Inc. | Bispecific antigen-binding molecules and methods of use |
JP7326345B2 (ja) | 2018-02-09 | 2023-08-15 | ジェンマブ アクティーゼルスカブ | Cd3及びcd20に対する二重特異性抗体を含む医薬組成物及びそれらの使用 |
WO2019175658A1 (en) * | 2018-03-14 | 2019-09-19 | Novimmune Sa | Anti-cd3 epsilon antibodies and methods of use thereof |
CN110540593B (zh) * | 2018-05-29 | 2022-05-17 | 上海药明生物技术有限公司 | 新型的抗cd3/抗cd20双特异性抗体 |
WO2019244107A1 (en) * | 2018-06-21 | 2019-12-26 | Daiichi Sankyo Company, Limited | Compositions including cd3 antigen binding fragments and uses thereof |
CN109836502B (zh) * | 2018-11-12 | 2021-09-07 | 浙江大学 | 一种双特异性抗体及其应用 |
WO2020168555A1 (zh) * | 2019-02-22 | 2020-08-27 | 武汉友芝友生物制药有限公司 | Cd3抗原结合片段及其应用 |
CN110551221B (zh) * | 2019-07-02 | 2021-03-05 | 广州爱思迈生物医药科技有限公司 | 一种双特异性抗体及其制备方法与应用 |
US20220411505A1 (en) | 2019-08-15 | 2022-12-29 | Genmab A/S | Pharmaceutical compositions comprising bispecific antibodies directed against cd3 and cd20 and their uses |
CN111100204B (zh) * | 2019-11-26 | 2022-03-11 | 山东立菲生物产业有限公司 | 靶向cd20的抗体、其制备方法和应用 |
PE20221511A1 (es) | 2019-12-13 | 2022-10-04 | Genentech Inc | Anticuerpos anti-ly6g6d y metodos de uso |
CN113402612A (zh) * | 2020-03-17 | 2021-09-17 | 西比曼生物科技(香港)有限公司 | 靶向cd19和cd20的联合嵌合抗原受体及其应用 |
CR20220521A (es) | 2020-03-18 | 2023-01-23 | Genmab As | Anticuerpos |
KR20230008775A (ko) * | 2020-05-08 | 2023-01-16 | 젠맵 에이/에스 | Cd3 및 cd20에 대한 이중특이적 항체 |
US10981996B1 (en) * | 2020-06-01 | 2021-04-20 | Abexxa Biologics, Inc. | Antibodies targeting a complex comprising non-classical HLA-I and neoantigen and their methods of use |
US20220033504A1 (en) * | 2020-06-01 | 2022-02-03 | Abexxa Biologics, Inc. | Antibodies targeting a complex comprising non-classical hla-i and neoantigen and their methods of use |
EP4210744A1 (en) | 2020-09-10 | 2023-07-19 | Genmab A/S | Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma |
JP2023542092A (ja) * | 2020-09-10 | 2023-10-05 | ジェンマブ エー/エス | びまん性大細胞型b細胞リンパ腫を治療するための併用療法におけるcd3及びcd20に対する二重特異性抗体 |
CN116437956A (zh) | 2020-09-10 | 2023-07-14 | 健玛保 | 用于治疗慢性淋巴细胞白血病的针对cd3和cd20的双特异性抗体 |
BR112023004351A2 (pt) | 2020-09-10 | 2023-04-04 | Genmab As | Método para tratar linfoma folicular em um sujeito humano |
JP2023541860A (ja) * | 2020-09-10 | 2023-10-04 | ジェンマブ エー/エス | びまん性大細胞型b細胞リンパ腫を治療するための併用療法におけるcd3及びcd20に対する二重特異性抗体 |
US20230357440A1 (en) * | 2020-09-10 | 2023-11-09 | Genmab A/S | Bispecific antibody against cd3 and cd20 in combination therapy for treating follicular lymphoma |
WO2022165171A1 (en) | 2021-01-28 | 2022-08-04 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for treating cytokine release syndrome |
EP4304616A1 (en) * | 2021-03-10 | 2024-01-17 | H. Lee Moffitt Cancer Center & Research Institute, Inc. | Compositions and methods to reduce therapeutic t cell toxicity |
WO2022189667A1 (en) * | 2021-03-12 | 2022-09-15 | Genmab A/S | Non-activating antibody variants |
US20230241211A1 (en) | 2022-01-28 | 2023-08-03 | Genmab A/S | Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma |
US20230303693A1 (en) | 2022-01-28 | 2023-09-28 | Genmab A/S | Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma |
US20230357446A1 (en) | 2022-04-11 | 2023-11-09 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for universal tumor cell killing |
US11958906B2 (en) | 2022-04-13 | 2024-04-16 | Genentech, Inc. | Pharmaceutical compositions of mosunetuzumab and methods of use |
WO2023198839A2 (en) | 2022-04-13 | 2023-10-19 | Genmab A/S | Bispecific antibodies against cd3 and cd20 |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SI1558648T1 (sl) * | 2002-10-17 | 2012-05-31 | Genmab As | Človeška monoklonalna protitelesa proti CD |
AU2006301492B2 (en) * | 2005-10-11 | 2011-06-09 | Amgen Research (Munich) Gmbh | Compositions comprising cross-species-specific antibodies and uses thereof |
EP2155790A1 (en) * | 2007-05-31 | 2010-02-24 | Genmab A/S | Method for extending the half-life of exogenous or endogenous soluble molecules |
AU2009299794B2 (en) * | 2008-10-01 | 2015-08-13 | Amgen Research (Munich) Gmbh | Cross-species-specific single domain bispecific single chain antibody |
UY32808A (es) | 2009-07-29 | 2011-02-28 | Abbott Lab | Inmunoglobulinas como dominio variable dual y usos de las mismas |
US9493578B2 (en) | 2009-09-02 | 2016-11-15 | Xencor, Inc. | Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens |
SI2519543T1 (sl) | 2009-12-29 | 2016-08-31 | Emergent Product Development Seattle, Llc | Beljakovine, ki se vežejo s heterodimeri in njihova uporaba |
US9150663B2 (en) * | 2010-04-20 | 2015-10-06 | Genmab A/S | Heterodimeric antibody Fc-containing proteins and methods for production thereof |
AR084053A1 (es) * | 2010-11-30 | 2013-04-17 | Chugai Pharmaceutical Co Ltd | Agente terapeutico que induce citotoxicidad |
CN103796677B (zh) * | 2011-04-20 | 2019-08-16 | 健玛保 | 针对her2和cd3的双特异性抗体 |
SG195072A1 (en) | 2011-05-21 | 2013-12-30 | Macrogenics Inc | Cd3-binding molecules capable of binding to human and non-human cd3 |
CN103748114B (zh) | 2011-08-23 | 2017-07-21 | 罗切格利卡特公司 | T细胞活化性双特异性抗原结合分子 |
US11180572B2 (en) * | 2012-07-06 | 2021-11-23 | Genmab B.V. | Dimeric protein with triple mutations |
JOP20200236A1 (ar) * | 2012-09-21 | 2017-06-16 | Regeneron Pharma | الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها |
EP2961770A1 (en) | 2013-02-26 | 2016-01-06 | Roche Glycart AG | Bispecific t cell activating antigen binding molecules |
RU2015140915A (ru) | 2013-02-26 | 2017-04-03 | Роше Гликарт Аг | Биспецифические антигенсвязывающие молекулы, активирующие т-клетки |
US10465006B2 (en) | 2013-07-05 | 2019-11-05 | Genmab A/S | Humanized or chimeric CD3 antibodies |
RU2016104130A (ru) * | 2013-07-12 | 2017-08-17 | Займворкс Инк. | Биспецифичные конструкции, связывающие антигены cd3 и cd19 |
DK3083689T3 (da) * | 2013-12-17 | 2020-08-03 | Genentech Inc | Anti-CD3-antistoffer og fremgangsmåder til anvendelse |
TWI701042B (zh) | 2014-03-19 | 2020-08-11 | 美商再生元醫藥公司 | 用於腫瘤治療之方法及抗體組成物 |
WO2016081490A1 (en) | 2014-11-17 | 2016-05-26 | Regeneron Pharmaceuticals, Inc. | Methods for tumor treatment using cd3xcd20 bispecific antibody |
WO2017210485A1 (en) | 2016-06-01 | 2017-12-07 | Xencor, Inc. | Bispecific antibodies that bind cd20 and cd3 for use in the treatment of lymphoma |
EP3668898B1 (en) * | 2017-08-14 | 2023-07-05 | MorphoSys AG | Humanized antibodies for cd3 |
US20230357440A1 (en) * | 2020-09-10 | 2023-11-09 | Genmab A/S | Bispecific antibody against cd3 and cd20 in combination therapy for treating follicular lymphoma |
-
2016
- 2016-01-08 AU AU2016205967A patent/AU2016205967B2/en active Active
- 2016-01-08 CN CN201680014755.4A patent/CN107660214B/zh active Active
- 2016-01-08 JP JP2017536356A patent/JP6853176B2/ja active Active
- 2016-01-08 US US15/541,594 patent/US10544220B2/en active Active
- 2016-01-08 CN CN202210117824.1A patent/CN114478792A/zh active Pending
- 2016-01-08 EA EA201791554A patent/EA201791554A1/ru unknown
- 2016-01-08 CA CA2973159A patent/CA2973159A1/en active Pending
- 2016-01-08 KR KR1020177021738A patent/KR20170128222A/ko active IP Right Grant
- 2016-01-08 MX MX2017008875A patent/MX2017008875A/es unknown
- 2016-01-08 WO PCT/EP2016/050296 patent/WO2016110576A1/en active Application Filing
- 2016-01-08 UA UAA201708112A patent/UA120286C2/uk unknown
- 2016-01-08 BR BR112017014551-0A patent/BR112017014551A2/pt active Search and Examination
- 2016-01-08 EP EP16700133.8A patent/EP3242682A1/en active Pending
- 2016-01-08 SG SG11201705496SA patent/SG11201705496SA/en unknown
-
2017
- 2017-06-25 IL IL253166A patent/IL253166B/en unknown
- 2017-07-04 MX MX2022004082A patent/MX2022004082A/es unknown
-
2019
- 2019-12-04 US US16/702,996 patent/US20200199231A1/en active Pending
-
2021
- 2021-03-11 JP JP2021038857A patent/JP7177317B2/ja active Active
-
2022
- 2022-01-18 IL IL289946A patent/IL289946A/en unknown
- 2022-02-10 AU AU2022200871A patent/AU2022200871A1/en active Pending
- 2022-10-07 JP JP2022162493A patent/JP2023002615A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
US10544220B2 (en) | 2020-01-28 |
EA201791554A1 (ru) | 2017-12-29 |
EP3242682A1 (en) | 2017-11-15 |
AU2022200871A1 (en) | 2022-03-03 |
IL253166B (en) | 2022-02-01 |
IL253166A0 (en) | 2017-08-31 |
AU2016205967A1 (en) | 2017-07-27 |
AU2016205967B2 (en) | 2021-11-11 |
JP2021104020A (ja) | 2021-07-26 |
IL289946A (en) | 2022-03-01 |
JP6853176B2 (ja) | 2021-03-31 |
CA2973159A1 (en) | 2016-07-14 |
BR112017014551A2 (pt) | 2018-05-15 |
KR20170128222A (ko) | 2017-11-22 |
JP2023002615A (ja) | 2023-01-10 |
MX2022004082A (es) | 2022-05-03 |
US20200199231A1 (en) | 2020-06-25 |
SG11201705496SA (en) | 2017-08-30 |
JP7177317B2 (ja) | 2022-11-24 |
CN107660214A (zh) | 2018-02-02 |
UA120286C2 (uk) | 2019-11-11 |
CN107660214B (zh) | 2022-02-08 |
US20170355767A1 (en) | 2017-12-14 |
CN114478792A (zh) | 2022-05-13 |
WO2016110576A1 (en) | 2016-07-14 |
JP2018508188A (ja) | 2018-03-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2022004082A (es) | Anticuerpos biespecificos contra cd3 y cd20. | |
JOP20200192A1 (ar) | أجسام مضادة لـ tigit | |
PH12018502429A1 (en) | Antibody molecules for cancer treatment | |
PH12018500363A1 (en) | Bispecific monovalent diabodies that are capable of binding b7-h3 and cd3, and uses thereof | |
PH12018500711A1 (en) | Anti-pd1 antibodies and methods of use | |
PH12018501177A1 (en) | Antibodies targeting fc receptor-like 5 and methods of use | |
PH12017500322A1 (en) | Anti-her2 antibodies and immunoconjugates | |
MX2018003936A (es) | Anticuerpos anti proteina de muerte celular programada 1 (pd-1) y composiciones. | |
PH12017501521A1 (en) | Anti-dll3 chimeric antigen receptors and methods of use | |
NZ732568A (en) | Antibodies targeting b-cell maturation antigen and methods of use | |
PH12019500923A1 (en) | Anti-pd-1 antibodies and compositions | |
MX2022007522A (es) | Anticuerpos anti-cd27. | |
NZ731467A (en) | Anti-tim3 antibodies and methods of use | |
MX2017004715A (es) | Anticuerpos anti-ox40 humanizados y usos de los mismos. | |
TN2017000106A1 (en) | Bi-specific monovalent diabodies that are capable of binding cd19 and cd3, and uses thereof | |
NZ733055A (en) | Anti-c10orf54 antibodies and uses thereof | |
GEP20217317B (en) | Combination therapy for the treatment of cancer | |
PH12016501547A1 (en) | Anti-il-13/il-17 bispecific antibodies and uses thereof | |
MX2018004121A (es) | Receptores de antigeno y usos de los mismos. | |
MX2017007097A (es) | Combinacion de anticuerpos anti-cs1 y anti-muerte programada 1 (pd1) para tratar cancer (mieloma). | |
MX2019014090A (es) | Métodos para el tratamiento de la reservoritis crónica. | |
EA201691907A1 (ru) | Комбинированная терапия кураксинами |